Sanofi EBITDA Margin 2010-2024 | SNY

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Sanofi (SNY) over the last 10 years. The current EBITDA margin for Sanofi as of March 31, 2024 is .
Sanofi EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $50.68B $8.45B 16.67%
2023-12-31 $50.27B $9.59B 19.08%
2023-09-30 $49.01B $10.30B 21.03%
2023-06-30 $48.42B $11.11B 22.95%
2023-03-31 $48.20B $10.71B 22.21%
2022-12-31 $47.82B $10.72B 22.42%
2022-09-30 $48.72B $12.21B 25.07%
2022-06-30 $46.20B $10.43B 22.58%
2022-03-31 $46.31B $11.73B 25.32%
2021-09-30 $45.31B $11.37B 25.10%
2021-03-31 $43.57B $10.31B 23.66%
2020-09-30 $42.75B $9.32B 21.80%
2020-03-31 $41.19B $7.94B 19.28%
2019-09-30 $41.49B $6.79B 16.37%
2019-03-31 $41.50B $6.71B 16.17%
2018-03-31 $41.43B $6.77B 16.33%
2017-12-31 $40.92B $7.07B 17.27%
2017-09-30 $40.25B $7.72B 19.19%
2017-06-30 $39.59B $8.01B 20.24%
2017-03-31 $39.14B $8.14B 20.79%
2016-12-31 $38.41B $7.59B 19.77%
2016-09-30 $39.27B $8.06B 20.52%
2016-06-30 $39.37B $7.47B 18.97%
2016-03-31 $41.16B $7.72B 18.76%
2015-09-30 $42.97B $7.96B 18.53%
2015-06-30 $43.92B $11.02B 25.10%
2014-06-30 $44.70B $11.47B 25.67%
2013-06-30 $45.22B $11.54B 25.53%
2012-06-30 $46.75B $12.18B 26.06%
2012-03-31 $47.10B $8.41B 17.86%
2011-12-31 $47.27B $8.89B 18.80%
2011-09-30 $45.65B $8.20B 17.97%
2011-06-30 $44.35B $8.97B 20.23%
2011-03-31 $42.93B $10.32B 24.03%
2010-12-31 $41.26B $9.22B 22.33%
2010-09-30 $41.28B $8.91B 21.59%
2010-06-30 $41.42B $8.83B 21.33%
2010-03-31 $41.35B $8.80B 21.28%
2009-12-31 $40.79B $8.81B 21.60%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11